![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
XJ Zhao, H Yokoyama, K Chiba, S Wanwimolruk and T Ishizaki
Department of Clinical Pharmacology, International Medical Center of Japan, Tokyo, Japan.
Studies using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms (CYP1A1, 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 and 3A4) were performed to identify the CYP isoform(s) involved in the major metabolic pathway (3-hydroxylation) of quinine in humans. Eadie-Hofstee plots for the formation of 3-hydroxyquinine exhibited apparently monophasic behavior for all of the 10 different microsomal samples studies. There was interindividual variability in the kinetic parameters, as follows: 1.8-, 3.2- and 3.5-fold for K(m) Vmax and Vmax/K(m), respectively. The mean +/- S.D. values for K(m), Vmax and Vmax/K(m) were 106.1 +/- 19.3 microM, 1.33 +/- 0.48 nmol/mg protein/min and 12.8 +/- 5.1 microliters/mg protein/min, respectively. With 10 different human liver microsomes, the relationships between the 3- hydroxylation of quinine and the metabolic activities for substrates of the respective CYP isoforms were evaluated. The 3-hydroxylation of quinine showed an excellent correlation (r = 0.986, P < .001) with 6 beta-hydroxylation of testosterone, a marker substrate for CYP3A4. A significant correlation (r = 0.768, P < .01) between the quinine 3- hydroxylase and S-mephenytoin 4'-hydroxylase activities was also observed. However, no significant correlation existed between the 3- hydroxylation of quinine and the oxidative activities for substrates for CYP1A2 (phenacetin), 2C9 (diclofenac), 2D6 (desipramine) and 2E1 (chlorzoxazone). Ketoconazole and troleandomycin (inhibitors of CYP3A4) inhibited the 3-hydroxylation of quinine by human liver microsomes with respective mean IC50 values of 0.026 microM and 28.9 microM. Anti-CYP3A antibodies strongly inhibited quinine 3-hydroxylation, whereas weak inhibition was observed in the presence of S-mephenytoin or anti-CYP2C antibodies. Among the nine recombinant human CYP isoforms, CYP3A4 exhibited the highest catalytic activity with respect to the 3- hydroxylation of quinine, compared with the minor activity of CYP2C19 and little discernible or no effect of other CYP isoforms. Collectively, these data suggest that the 3-hydroxylation of quinine is mediated mainly by CYP3A4 and to a minor extent by CYP2C19. Other CYP isoforms used herein appear to be of negligible importance in this major pathway of quinine in humans.
This article has been cited by other articles:
|
|
 |
|
  T. Matsunaga, N. Kishi, S. Higuchi, K. Watanabe, T. Ohshima, and I. Yamamoto CYP3A4 Is a Major Isoform Responsible for Oxidation of 7-Hydroxy-Delta 8-tetrahydrocannabinol to 7-Oxo-Delta 8-tetrahydrocannabinol in Human Liver Microsomes Drug Metab. Dispos., November 1, 2000; 28(11): 1291 - 1296. [Abstract] [Full Text]
|
|
|
|
|
|
A. Suzuki, I. Iida, F. Tanaka, M. Akimoto, K. Fukushima, M. Tani, T. Ishizaki, and K. Chiba Identification of Human Cytochrome P-450 Isoforms Involved in Metabolism of R(+)- and S(-)-Gallopamil: Utility of In Vitro Disappearance Rate Drug Metab. Dispos., November 1, 1999; 27(11): 1254 - 1259. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Ekins, G. Bravi, J. H. Wikel, and S. A. Wrighton Three-Dimensional-Quantitative Structure Activity Relationship Analysis of Cytochrome P-450 3A4 Substrates J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 424 - 433. [Abstract] [Full Text]
|
|
|
|
|
|
X.-J. Zhao, E. Koyama, and T. Ishizaki An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes Drug Metab. Dispos., July 1, 1999; 27(7): 776 - 785. [Abstract] [Full Text]
|
|
|
|
|
|
T. L. Nielsen, B. B. Rasmussen, J.-P. Flinois, P. Beaune, and K. Brøsen In Vitro Metabolism of Quinidine: The (3S)-3-Hydroxylation of Quinidine Is a Specific Marker Reaction for Cytochrome P-4503A4 Activity in Human Liver Microsomes J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 31 - 37. [Abstract] [Full Text]
|
|
|
|
|
|
T. Kawashiro, K. Yamashita, X.-J. Zhao, E. Koyama, M. Tani, K. Chiba, and T. Ishizaki A Study on the Metabolism of Etoposide and Possible Interactions with Antitumor or Supporting Agents by Human Liver Microsomes J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1294 - 1300. [Abstract] [Full Text]
|
|
|
|
|
|
X.-J. Zhao, T. Kawashiro, and T. Ishizaki Mutual Inhibition between Quinine and Etoposide by Human Liver Microsomes. Evidence for Cytochrome P4503A4 Involvement in Their Major Metabolic Pathways Drug Metab. Dispos., February 1, 1998; 26(2): 188 - 191. [Abstract] [Full Text]
|
|
|
|
|
|
X.-J. Zhao and T. Ishizaki The In Vitro Hepatic Metabolism of Quinine in Mice, Rats and Dogs: Comparison with Human Liver Microsomes J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1168 - 1176. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
